Combination of Toripalimab and JS004 Therapy for ccRCC

NCT06690697 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG: JS004
DRUG: Toripalimab
DRUG: Axitinib
DRUG: Sorafenib

Sponsor

Fudan University